Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
IRTC 
iRhythm Technologies Inc (IRTC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/04/2025: IRTC (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -14.1% | Avg. Invested days 39 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/04/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 3.15B USD | Price to earnings Ratio - | 1Y Target Price 133 |
Price to earnings Ratio - | 1Y Target Price 133 | ||
Volume (30-day avg) 426294 | Beta 1.45 | 52 Weeks Range 55.92 - 128.52 | Updated Date 04/6/2025 |
52 Weeks Range 55.92 - 128.52 | Updated Date 04/6/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.63 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -19.14% | Operating Margin (TTM) -0.83% |
Management Effectiveness
Return on Assets (TTM) -6.54% | Return on Equity (TTM) -75.27% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 3352682873 | Price to Sales(TTM) 5.33 |
Enterprise Value 3352682873 | Price to Sales(TTM) 5.33 | ||
Enterprise Value to Revenue 5.66 | Enterprise Value to EBITDA -34.37 | Shares Outstanding 31409600 | Shares Floating 31001606 |
Shares Outstanding 31409600 | Shares Floating 31001606 | ||
Percent Insiders 0.82 | Percent Institutions 113.54 |
Analyst Ratings
Rating 4.46 | Target Price 106.83 | Buy 3 | Strong Buy 8 |
Buy 3 | Strong Buy 8 | ||
Hold 2 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
iRhythm Technologies Inc
Company Overview
History and Background
iRhythm Technologies, Inc. was founded in 2006. It is a digital healthcare company focused on cardiac rhythm diagnostics and monitoring. The company developed the Zio service to improve arrhythmia detection and patient care.
Core Business Areas
- Cardiac Monitoring: iRhythm's primary business involves developing and commercializing the Zio service, a wearable biosensor used for long-term continuous monitoring of heart rhythms to detect and diagnose arrhythmias.
Leadership and Structure
Quentin Blackford is the CEO. The company has a typical corporate structure with departments like R&D, sales, marketing, and operations, reporting to the executive team and board of directors.
Top Products and Market Share
Key Offerings
- Zio XT: A wearable sensor that continuously records ECG data for up to 14 days. It is used to detect various heart rhythm abnormalities. Market share is estimated to be around 25%. Competitors include Medtronic, Boston Scientific and Abbott.
Market Dynamics
Industry Overview
The cardiac monitoring market is growing due to an aging population, increasing prevalence of heart disease, and advancements in wearable technology.
Positioning
iRhythm differentiates itself with its focus on long-term continuous monitoring, AI-powered analysis, and ease of use.
Total Addressable Market (TAM)
The TAM for cardiac monitoring is estimated to be in the billions of dollars. iRhythm is positioned to capture a significant share of this market with its innovative Zio service.
Upturn SWOT Analysis
Strengths
- Innovative technology
- Strong brand recognition
- Established market presence
- High customer satisfaction
Weaknesses
- Reliance on single product
- Reimbursement challenges
- Regulatory risks
- Limited geographic diversification
Opportunities
- Expanding product line
- Entering new geographic markets
- Strategic partnerships
- Improving reimbursement coverage
Threats
- Increased competition
- Technological obsolescence
- Economic downturn
- Adverse regulatory changes
Competitors and Market Share
Key Competitors
- MDT
- ABT
- BSX
Competitive Landscape
iRhythm competes with larger medical device companies like Medtronic, Abbott, and Boston Scientific. iRhythm's advantage lies in its focus on long-term continuous monitoring and AI-powered analysis.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: iRhythm has experienced significant revenue growth in recent years, driven by increased adoption of its Zio service.
Future Projections: Analysts expect iRhythm to continue growing at a rapid pace, driven by increasing demand for cardiac monitoring solutions.
Recent Initiatives: iRhythm has been focused on expanding its product line, entering new geographic markets, and improving its reimbursement coverage.
Summary
iRhythm is a moderately strong company with its innovative Zio service and established market presence in cardiac monitoring. Its reliance on a single product poses a risk, and reimbursement challenges remain a concern. Successful execution of its growth strategies, including expanding its product line and geographic reach, is crucial for continued success, as it is challenged by larger players.
Similar Companies
ABT
Abbott Laboratories
ABT
Abbott Laboratories
BSX
Boston Scientific Corp
BSX
Boston Scientific Corp
MDT
Medtronic PLC
MDT
Medtronic PLC
Sources and Disclaimers
Data Sources:
- Company Filings
- Analyst Reports
- Market Research Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market data and financial information may be outdated and/or inaccurate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About iRhythm Technologies Inc
Exchange NASDAQ | Headquaters San Francisco, CA, United States | ||
IPO Launch date 2016-10-20 | President, CEO & Director Mr. Quentin S. Blackford | ||
Sector Healthcare | Industry Medical Devices | Full time employees 2000 | Website https://www.irhythmtech.com |
Full time employees 2000 | Website https://www.irhythmtech.com | ||
iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology that provides ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. The company offers Zio ambulatory cardiac monitoring services, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. It also provides Zio Monitor System, a prescription-only remote electrocardiogram (ECG) monitoring system consisting a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days; Zio XT System, a prescription-only remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and Zio ECG Utilization Software System, which supports the capture and analysis of ECG data. In addition, the company offers Zio AT System, a prescription-only remote ECG monitoring system, which consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days, as well as incorporates the Zio AT wireless gateway to provide connectivity between the patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products. iRhythm Technologies, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.